Investor directory

Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Top Stages

Acquisition
http://compasstherapeutics.com
https://crunchbase.com/organization/compass-therapeutics
https://facebook.com/compasstherapeutics
https://linkedin.com/company/compass-therapeutics-llc
https://twitter.com/compassbio
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=266166780

Errik Anderson

Co-Founder, President / COO

1 past transactions

TRIGR Therapeutics

Acquisition in 2021
TRIGR Therapeutics is a privately-owned company focused on the development and commercialization of novel therapeutics for unmet medical needs. The company's immunotherapy pre-clinical pipeline consists of off the shelf products in contrast to CAR-T and other cellular processes which have delivered impressive clinical results while requiring complicated manufacturing processes and lead time to treat patients. TRIGR is building an asset portfolio of clinical-stage and pre-clinical antibodies that will represent the next wave in cancer immunotherapy. they currently have partnered with innovative R&D companies, such as ABL Bio in South Korea, and will develop selected ABL programs into approved immunotherapies worldwide. TRIGR’s diversified pipeline currently consists of immunotherapies against novel and validated targets that have the potential to overcome and modulate biological barriers (e.g. tumor micro-environment) to result in successful treatment outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.